title: Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part II: Management of stage IV disease.
abstract: Part II of this continuing medical education article will discuss the treatment options for stage IV melanoma, including novel therapies, such as ipilimumab and vemurafenib; established therapies, including high-dose interleukin-2, conventional chemotherapy, and biochemotherapy; and additional therapies currently under investigation in the form of clinical trials. The approach to patients with brain metastases will be discussed, as will recommendations for distress screening and defining aspects of palliative care.
authors.affiliation: Department of Dermatology, University of Michigan Medical School and Comprehensive Cancer Center, Ann Arbor, Michigan, USA. matfox@med.umich.edu
authors.forename: Matthew C
authors.initials: MC
authors.lastname: Fox
authors.forename: Christopher D
authors.initials: CD
authors.lastname: Lao
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Schwartz
authors.forename: Marcus L
authors.initials: ML
authors.lastname: Frohm
authors.forename: Christopher K
authors.initials: CK
authors.lastname: Bichakjian
authors.forename: Timothy M
authors.initials: TM
authors.lastname: Johnson
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000556:secondary* / Q000628:therapy*; D003606:Dacarbazine / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007211:Indoles / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D000074324:Ipilimumab; D008545:Melanoma / Q000556:secondary* / Q000628:therapy*; D009367:Neoplasm Staging; D010166:Palliative Care; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics; D016634:Radiosurgery; D012878:Skin Neoplasms / Q000473:pathology* / Q000628:therapy*; D013449:Sulfonamides / Q000627:therapeutic use; D000077484:Vemurafenib; D048490:raf Kinases / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D007211:Indoles; D007376:Interleukin-2; D000074324:Ipilimumab; D013449:Sulfonamides; D000077484:Vemurafenib; D003606:Dacarbazine; D011505:Protein-Tyrosine Kinases; D019009:Proto-Oncogene Proteins c-kit; D048490:raf Kinases